- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04629144
Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis) (TRIBECA)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: David Saadoun, MD PhD
- Phone Number: 33 142499742
- Email: david.saadoun@aphp.fr
Study Contact Backup
- Name: Matthieu RESCHE-RIGON, MD PhD
- Phone Number: 33 142499742
- Email: matthieu.resche-rigon@u-paris.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- Written inform consent
- Active cryoglobulinemia vasculitis define by positive cryoglobulinemia and a clinically active vasculitis with skin, joint, renal, peripheral nerve, central neurological, digestive, pulmonary and/or cardiac involvement (no histological evidence needed if presence of purpura demonstrated),
- Affiliated to National French social security system
- Having received Rituximab as induction therapy within 6 weeks
- Female subjects of childbearing potential must not become pregnant and so must be sexually inactive by abstinence or use contraceptive methods with a failure rate of < 1%.
Therefore, these women must have a negative serum pregnancy test at screening, and confirmed monthly while in study, out to at least 4 months (5 half lives) post last dose and agree to 1 of the following:
- Complete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent until 16 weeks after the last dose of study agent (Sexual inactivity by abstinence must be consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception) OR
Consistent and correct use of 1 of the following acceptable methods of birth control for 1 month prior to the start of the study agent, during the study, and 16 weeks after the last dose of study agent
- Oral contraceptive, either combined or progestogen alone
- Injectable progestogen
- Implants of levonorgestrel or etonogestrel
- Estrogenic vaginal ring
- Percutaneous contraceptive patches
- Intrauterine device (IUD) or intrauterine system (IUS) with <1% failure rate as stated in the product label
- Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records
- Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository) These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring subjects understand how to properly use these methods of contraception.
- HIV negative serology ; negative HBs Ag test and HBc Ab test; HCV negative serology or negative HCV RNA if positive HCV serology
Adequate haematological status:
- neutrophils (ANC) >1x109/L;
Exclusion Criteria:
- Patient with a vasculitis unrelated to cryoglobulinemia
- Patient with non active cryoglobulinemia vasculitis,
- Patient with immunosuppressant introduced or increased in the month prior to the inclusion, (except Rituximab)
- Patients receiving corticosteroid therapy > 0.5 mg/kg/d > 1 month before the inclusion or > 1 mg/kg/d >2 weeks before inclusion or taking more than 3000 mg methylprednisolone 4 weeks prior to the inclusion visit
- Excluded concomitant medications (except Rituximab) :
365 days Prior to Belimumab:
Any biologic investigational agent (e.g., abetimus sodium, anti CD40L antibody, BG9588/ IDEC 131)
- Investigational agent applies to any drug not approved for sale in the country in which it is being used
180 Days Prior to Belimumab:
Intravenous cyclophosphamide
- If concomitant use with cyclophosphamide, enhanced safety monitoring required.
- Serum IgG levels should be measured monthly in this situation
- Benlysta should be discontinued in subjects with serum IgG levels <250 mg/dL associated with a severe or serious infection
30 Days Prior to Belimumab (or 7 half lives, whichever is greater)
Any non-biologic investigational agent
- Investigational agent applies to any drug not approved for sale in the country in which it is being use
- Live vaccines within 30 days prior to baseline or concurrently with belimumab
- Have a history of malignant neoplasm within the last 5 years
- Have a Progressive multifocal leukoencephalopathy
- .
- Have evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and/or any suicidal ideation in the last 2 months or who in the investigator's judgment, pose a significant suicide risk
- Have a history of a primary immunodeficiency
- Have a significant IgG deficiency (IgG level < 400 mg/dL)
- Have a history of major organ transplant or hematopoietic stem cell/marrow transplant or renal transplant.
- • Have an IgA deficiency (IgA level < 10 mg/dL
Infection history:
- Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus,)
- Infection requiring hospitalization and/or use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti-parasitic agents) within 60 days of Day 0.
- Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 365 days prior to Day 0
- Have a historically positive HIV test or test positive at screening for HIV
Hepatitis status:
- Serologic evidence of current or past Hepatitis B (HB) infection based on the results of testing for HBsAg and HBcAb as follows:
Patients positive for HBsAg or HBcAb are excluded
- Positive test for Hepatitis C RNA
- Have a history of a hypersensitivity or an anaphylactic reaction to parenteral administration of Belimumab or Rituximab, corticosteroids or any excipients of the treatments administered during the study
- If Women of Child Bearing Potential (WCBP) are included please see special instructions above
- Pregnant or breast feeding women
- Have any intercurrent significant medical or psychiatric illness that the investigator considers would make the candidate unsuitable for the study
- Patients under legal protection or unable to consent
- Participation to another interventional study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Belimumab
Belimumab administered subcutaneously 200mg weekly from week 0 to week 24.
|
Belimumab administered subcutaneously 200mg weekly from week 0 to week 24. Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:
|
Placebo Comparator: Placebo
Placebo of Belimumab administered subcutaneously weekly from week 0 to week 24.
|
Both arms will have the same corticosteroid tapering scheme, with an initial dose of 60 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete clinical response rate W24
Time Frame: Week 24
|
The complete clinical response is defined by the remission of all affected organs involved at baseline and the absence of clinical relapse.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety W24
Time Frame: Week 24
|
Frequency and severity of adverse clinical events
|
Week 24
|
Safety W48
Time Frame: Week 48
|
Frequency and severity of adverse clinical events
|
Week 48
|
Response W12
Time Frame: Week 12
|
The complete clinical response is defined by the remission of all affected organs involved at baseline and the absence of clinical relapse. Partial clinical response The partial clinical response is defined by the improvement and / or remission of more than half of the organ involvement present at baseline and the absence of clinical relapse. No clinical response Patients with no clinical response at W4 will be defined by worsening of ulcers or cutaneous necrosis, worsening peripheral neurological involvement or by persistence of active renal involvement defined by persistence of proteinuria> 1.5 g / 24h or proteinuria/creatinuria <150 mg/mmol). |
Week 12
|
Response W24
Time Frame: Week 24
|
The complete clinical response is defined by the remission of all affected organs involved at baseline and the absence of clinical relapse. Partial clinical response The partial clinical response is defined by the improvement and / or remission of more than half of the organ involvement present at baseline and the absence of clinical relapse. No clinical response Patients with no clinical response at W4 will be defined by worsening of ulcers or cutaneous necrosis, worsening peripheral neurological involvement or by persistence of active renal involvement defined by persistence of proteinuria> 1.5 g / 24h or proteinuria/creatinuria <150 mg/mmol). |
Week 24
|
Response W48
Time Frame: Week 48
|
The complete clinical response is defined by the remission of all affected organs involved at baseline and the absence of clinical relapse. Partial clinical response The partial clinical response is defined by the improvement and / or remission of more than half of the organ involvement present at baseline and the absence of clinical relapse. No clinical response Patients with no clinical response at W4 will be defined by worsening of ulcers or cutaneous necrosis, worsening peripheral neurological involvement or by persistence of active renal involvement defined by persistence of proteinuria> 1.5 g / 24h or proteinuria/creatinuria <150 mg/mmol). |
Week 48
|
Rate of cryoglobulinemia clearance W12
Time Frame: Week 12
|
cryoglobulinemia clearance
|
Week 12
|
Rate of cryoglobulinemia clearance W24
Time Frame: Week 24
|
cryoglobulinemia clearance
|
Week 24
|
Rate of cryoglobulinemia clearance W48
Time Frame: Week 48
|
cryoglobulinemia clearance
|
Week 48
|
rheumatoid factor activity W12
Time Frame: Week 12
|
negativation of rheumatoid factor activity
|
Week 12
|
rheumatoid factor activity W24
Time Frame: Week 24
|
negativation of rheumatoid factor activity
|
Week 24
|
rheumatoid factor activity W48
Time Frame: Week 48
|
negativation of rheumatoid factor activity
|
Week 48
|
C4 complement level W12
Time Frame: Week 12
|
normalization of C4 complement level
|
Week 12
|
C4 complement level W24
Time Frame: Week 24
|
normalization of C4 complement level
|
Week 24
|
C4 complement level W48
Time Frame: Week 48
|
normalization of C4 complement level
|
Week 48
|
Early failures
Time Frame: Week 4
|
Rate of early failures (non clinical response at W4) Patients with no clinical response at W4 will be defined by worsening of ulcers or cutaneous necrosis, worsening peripheral neurological involvement or by persistence of active renal involvement defined by persistence of proteinuria> 1.5 g / 24h or proteinuria/creatinuria <150 mg/mmol,).
|
Week 4
|
Clinical relapse rate W48
Time Frame: Week 48
|
Relapse is defined as de novo appearance or recurrence of a manifestation of cryoglobulinemia vasculitis
|
Week 48
|
Prednisone W24
Time Frame: Week 24
|
Cumulative dose of prednisone
|
Week 24
|
Prednisone W48
Time Frame: Week 48
|
Cumulative dose of prednisone
|
Week 48
|
Quality of life W24
Time Frame: Week 24
|
Quality of life score SF-36. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. To calculate the scores it is necessary to purchase special software for the commercial version, but no special software is needed for the RAND-36 version. Pricing depends on the number of scores that the researcher needs to calculate. The eight sections are: vitality physical functioning bodily pain general health perceptions physical role functioning emotional role functioning social role functioning mental health |
Week 24
|
Quality of life W48
Time Frame: Week 48
|
Quality of life score SF-36. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. To calculate the scores it is necessary to purchase special software for the commercial version, but no special software is needed for the RAND-36 version. Pricing depends on the number of scores that the researcher needs to calculate. The eight sections are: vitality physical functioning bodily pain general health perceptions physical role functioning emotional role functioning social role functioning mental health |
Week 48
|
Infections
Time Frame: Week 48
|
Rate of infections
|
Week 48
|
BVAS activity W12
Time Frame: Week 12
|
BVAS activity score as defined in Flossmann, Oliver, et al. "Development of comprehensive disease assessment in systemic vasculitis."
Postgraduate medical journal 84.989 (2008): 143-152.
|
Week 12
|
BVAS activity W24
Time Frame: Week 24
|
BVAS activity score as defined in Flossmann, Oliver, et al. "Development of comprehensive disease assessment in systemic vasculitis."
Postgraduate medical journal 84.989 (2008): 143-152.
|
Week 24
|
BVAS activity W48
Time Frame: Week 48
|
BVAS activity score as defined in Flossmann, Oliver, et al. "Development of comprehensive disease assessment in systemic vasculitis."
Postgraduate medical journal 84.989 (2008): 143-152.
|
Week 48
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunomonitoring W4
Time Frame: Week 4
|
deep immunophenotyping, cytokines production, clonal IgM memoryCD21-/low cells) description
|
Week 4
|
Immunomonitoring W24
Time Frame: Week 24
|
deep immunophenotyping, cytokines production, clonal IgM memoryCD21-/low cells) description
|
Week 24
|
Immunomonitoring W48
Time Frame: Week 48
|
deep immunophenotyping, cytokines production, clonal IgM memoryCD21-/low cells) description
|
Week 48
|
renal response W12
Time Frame: Week 12
|
Renal remission is evaluated biologically (proteinuria <0.5g/24h or proteinuria/creatinuria <50 mg/mmol).
|
Week 12
|
renal response W24
Time Frame: Week 24
|
Renal remission is evaluated biologically (proteinuria <0.5g/24h or proteinuria/creatinuria <50 mg/mmol).
|
Week 24
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Vasculitis
- Cryoglobulinemia
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Belimumab
Other Study ID Numbers
- APHP180351
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasculitis
-
University Hospital, Strasbourg, FranceRecruiting
-
Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South University; Hunan Provincial People... and other collaboratorsRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedANCA-Associated VasculitisUnited Kingdom
-
Chinese SLE Treatment And Research GroupThe First Affiliated Hospital of Anhui Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingANCA Associated Vasculitis | Maintenance TherapyChina
-
University Hospital, BrestNot yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental ExposureFrance
-
University Hospital Birmingham NHS Foundation TrustMerck Sharp & Dohme LLCRecruitingANCA Associated VasculitisUnited Kingdom
-
Shanghai Zhongshan HospitalCompletedDrug Use | ANCA Associated Vasculitis | JAK-STAT Pathway DeregulationChina
-
University Hospital, BrestRecruiting
-
Nantes University HospitalINSERM UMRS-1064CompletedANCA-associated VasculitisFrance
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
Clinical Trials on Belimumab
-
Human Genome Sciences Inc.GlaxoSmithKlineCompletedSystemic Lupus ErythematosusUnited States, Spain, Israel, Netherlands, Canada, Germany, Poland, Romania, Puerto Rico, Costa Rica, Belgium, Slovakia, United Kingdom, Mexico, Italy, Austria, Czech Republic, Sweden, France
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineNo longer availableRheumatoid ArthritisUnited States
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineCompletedLupus Erythematosus, Discoid
-
Human Genome Sciences Inc.CompletedArthritis, RheumatoidUnited States
-
GlaxoSmithKlineCompleted
-
Human Genome Sciences Inc.CompletedLupus Erythematosus, SystemicUnited States, Canada
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineCompletedSystemic Lupus ErythematosusUnited States
-
Human Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineCompletedSystemic Lupus ErythematosusUnited States
-
Human Genome Sciences Inc.GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedGlomerulonephritis, MembranousUnited Kingdom